Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 10Adenocarcinoma, Bronchiolo-Alveolar 7Adenocarcinoma of Lung 6Lung Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Rectal Neoplasms 4Colonic Neoplasms 4Head and Neck Neoplasms 3Colorectal Neoplasms 3Skin Neoplasms 2Ovarian Neoplasms 2Gliosarcoma 2Glioblastoma 2Carcinoma, Ovarian Epithelial 2Breast Neoplasms 2Vipoma 1Uterine Cervical Neoplasms 1Untreated Childhood Anaplastic Astrocytoma 1Unspecified Childhood Solid Tumor, Protocol Specific 1Unspecified Adult Solid Tumor, Protocol Specific 1Tongue Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Somatostatinoma 1Solitary Fibrous Tumor, Pleural 1Salivary Gland Neoplasms 1Recurrent Uterine Corpus Carcinoma 1Parathyroid Neoplasms 1Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter 1

Interventions

Trastuzumab 2tipifarnib 1temsirolimus 1romidepsin 1antineoplaston AS 2-1 1antineoplaston A10 1Streptozocin 1Sorafenib 1Sirolimus 1Oxaliplatin 1Melphalan 1Leucovorin 1Interleukin-12 Subunit p35 1Interleukin-12 1Gefitinib 1Floxuridine 1Complementary Therapies 1Cisplatin 1Capecitabine 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Carcinoma, Islet Cell × Gefitinib × Clear all
NCT00075439 2013-06-04

Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 2 Completed
90 enrolled
Endocrine

Vipoma, Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡